Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel M Kaufman

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Neurologic Clinics|March 6, 2010
Negotiating with payersJoel M Kaufman
Neurology. Clinical Practice|February 15, 2018
How to work with insurance companiesJoel M Kaufman
The Journal of Sexual Medicine|September 3, 2008
Cylinder aneurysm of parylene-coated American Medical System (AMS) 700CX penile prosthesisJoel M Kaufman, Thomas E Weldon
The Journal of Urology|August 18, 2004
Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal menJoel M Kaufman, R James Graydon
Neurology. Clinical Practice|February 15, 2018
An analysis of AAN's evidence-based guideline for IVIg use in neurologic disorders: Provider impact and payer perspectivesSaty Satya-Murti, Katie M Shepard, Joel M Kaufman
Archives of Neurology|November 10, 2010
Role of professionalism in improving the patient-centeredness, timeliness, and equity of neurological careChristopher T Bever, Gary M Franklin, Joel M Kaufman, et al.
The Journal of Sexual Medicine|February 11, 2012
One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind studyJoel M Kaufman, Michael G Miller, Sherahe Fitzpatrick, et al.
Clinical Therapeutics|January 11, 2007
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT)Alan D Garely, Joel M Kaufman, Peter K Sand, et al.
BJU International|November 22, 2008
Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trialJoel M Kaufman, Raymond C Rosen, Ramagopal V Mudumbi, et al.
The Journal of Sexual Medicine|April 16, 2011
Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal menJoel M Kaufman, Michael G Miller, Jeffrey L Garwin, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Neurologic Clinics|March 6, 2010
Negotiating with payersJoel M Kaufman
Neurology. Clinical Practice|February 15, 2018
How to work with insurance companiesJoel M Kaufman
The Journal of Sexual Medicine|September 3, 2008
Cylinder aneurysm of parylene-coated American Medical System (AMS) 700CX penile prosthesisJoel M Kaufman, Thomas E Weldon
The Journal of Urology|August 18, 2004
Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal menJoel M Kaufman, R James Graydon
Neurology. Clinical Practice|February 15, 2018
An analysis of AAN's evidence-based guideline for IVIg use in neurologic disorders: Provider impact and payer perspectivesSaty Satya-Murti, Katie M Shepard, Joel M Kaufman
Archives of Neurology|November 10, 2010
Role of professionalism in improving the patient-centeredness, timeliness, and equity of neurological careChristopher T Bever, Gary M Franklin, Joel M Kaufman, et al.
The Journal of Sexual Medicine|February 11, 2012
One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind studyJoel M Kaufman, Michael G Miller, Sherahe Fitzpatrick, et al.
Clinical Therapeutics|January 11, 2007
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT)Alan D Garely, Joel M Kaufman, Peter K Sand, et al.
BJU International|November 22, 2008
Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trialJoel M Kaufman, Raymond C Rosen, Ramagopal V Mudumbi, et al.
The Journal of Sexual Medicine|April 16, 2011
Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal menJoel M Kaufman, Michael G Miller, Jeffrey L Garwin, et al.
Pageof 2